In contrast, several agents, such as cabozantinib (VEGFR, MET, RET), ABT-888 (PARP), dabrafenib (BRAF), imatinib (Bcr/Abl), and sunitinib (PDGFR), demonstrated relatively minimal anti-cancer activities [19]. Here, MET is linked to cancer.